Crestor Generics On Hold As FDA, AstraZeneca Talk About Exclusivity
This article was originally published in The Pink Sheet Daily
Court postpones a decision on a temporary restraining order and asks parties to reach agreement on how FDA is to proceed with pending ANDAs.
You may also be interested in...
Crestor Generics To Launch After 12-Day Delay
AstraZeneca's legal gambit results in almost two more weeks of sales for the statin even though the court ultimately agreed with FDA on labeling carve-out for orphan indication.
AstraZeneca Sues FDA On Crestor Generics: Fighting A 'Foregone Conclusion'?
Company is waging the same legal battle Otsuka lost last year, arguing pediatric orphan indication should block approvals of ANDAs.
Supreme Court Seems Ready To Uphold Ruling Against Amgen’s Anti-PCSK9 Antibody Patents
Justices question what Amgen’s invention covers in its dispute with Sanofi. They appear inclined to uphold Federal Circuit’s standard for enablement despite potential negative impact on genus claims.